Search
argenx SE
ARGXAdd to Watchlist
782.170USD
-5.140-0.65%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
49.16BMarket Cap
32.32P/E TTM
More Details of argenx SE Company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
argenx SE Info
Ticker SymbolARGX
Company nameargenx SE
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Number of employees1599
Security typeDepository Receipt
Fiscal year-endJul 10
AddressLaarderhoogtweg 25
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1101 EB
Phone31763030
Websitehttps://www.argenx.com/
Ticker SymbolARGX
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Company Executives of argenx SE
Name
Name/Position
Position
Shareholding
Change
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Dr. Luc Truyen
Dr. Luc Truyen
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
3.53B
85.13%
Rest of the World
342.62M
8.25%
Japan
206.84M
4.98%
China
67.92M
1.64%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, May 9
Updated: Sat, May 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.73%
T. Rowe Price Associates, Inc.
4.32%
Janus Henderson Investors
3.97%
Capital World Investors
3.10%
Artisan Partners Limited Partnership
2.84%
Other
77.05%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.73%
T. Rowe Price Associates, Inc.
4.32%
Janus Henderson Investors
3.97%
Capital World Investors
3.10%
Artisan Partners Limited Partnership
2.84%
Other
77.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.93%
Investment Advisor/Hedge Fund
17.71%
Hedge Fund
2.66%
Research Firm
0.90%
Private Equity
0.28%
Pension Fund
0.25%
Family Office
0.12%
Bank and Trust
0.08%
Venture Capital
0.01%
Other
49.06%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
942
31.47M
50.86%
-2.79M
2025Q4
855
32.28M
58.19%
+72.85K
2025Q3
891
32.22M
58.55%
-544.28K
2025Q2
847
32.65M
61.10%
-1.53M
2025Q1
821
34.16M
62.26%
-3.81M
2024Q4
770
34.96M
63.31%
-1.04M
2024Q3
718
36.05M
63.46%
+556.56K
2024Q2
690
35.13M
62.09%
+253.45K
2024Q1
672
34.89M
59.82%
-632.92K
2023Q4
654
33.46M
57.06%
+708.68K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.40M
8.73%
-77.80K
-1.42%
Dec 31, 2025
T. Rowe Price Associates, Inc.
2.67M
4.32%
-140.39K
-4.99%
Dec 31, 2025
Janus Henderson Investors
2.46M
3.97%
-117.09K
-4.55%
Dec 31, 2025
Capital World Investors
1.92M
3.1%
-43.27K
-2.21%
Dec 31, 2025
Artisan Partners Limited Partnership
1.76M
2.84%
-429.57K
-19.65%
Dec 31, 2025
Avoro Capital Advisors LLC
990.00K
1.6%
--
--
Dec 31, 2025
T. Rowe Price International Ltd
691.08K
1.12%
-137.70K
-16.61%
Dec 31, 2025
Wellington Management Company, LLP
679.24K
1.1%
-50.75K
-6.95%
Dec 31, 2025
RTW Investments L.P.
673.50K
1.09%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Biotech ETF
5.04%
iShares Neuroscience and Healthcare ETF
4.22%
Goldman Sachs Future Health Care Equity ETF
3.92%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
iShares Biotechnology ETF
3.12%
PGIM Jennison International Opportunities ETF
2.55%
ProShares Ultra Nasdaq Biotechnology
2.46%
Invesco Nasdaq Biotechnology ETF
2.44%
American Century Mid Cap Growth Impact ETF
1.63%
Invesco NASDAQ Next Gen 100 ETF
1.37%
View more
VanEck Biotech ETF
Proportion5.04%
iShares Neuroscience and Healthcare ETF
Proportion4.22%
Goldman Sachs Future Health Care Equity ETF
Proportion3.92%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.45%
iShares Biotechnology ETF
Proportion3.12%
PGIM Jennison International Opportunities ETF
Proportion2.55%
ProShares Ultra Nasdaq Biotechnology
Proportion2.46%
Invesco Nasdaq Biotechnology ETF
Proportion2.44%
American Century Mid Cap Growth Impact ETF
Proportion1.63%
Invesco NASDAQ Next Gen 100 ETF
Proportion1.37%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
